★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
CSL Limited (CSL) Moat Analysis
CSL Limited
CSL · ASX
Partial score covering 86% of segment weight.
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
CSL Limited reports CSL Behring, CSL Seqirus, and CSL Vifor. The clearest structural moat is Behring's vertically integrated plasma supply chain and dense collection network. Seqirus has durable government pandemic-preparedness relationships, including more than 30 agreements, but seasonal vaccine economics remain tender- and uptake-sensitive. Planned efficiency actions, routine regulatory approvals, capacity investment, reimbursement listings, and isolated HTA wins are not treated as standalone moats. Vifor is assigned no current moat after intensifying iron competition, impairment warnings, and the June 2026 CHMP recommendation to revoke TAVNEOS's EU authorization. CSL's May update reduced FY2026 constant-currency revenue and NPATA expectations to about US$15.2bn and US$3.1bn; the previously proposed Seqirus demerger is no longer targeted for FY2026.
Primary segment
CSL Behring
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
3 segments · 6 tags
Updated 2026-07-11
Segments
CSL Behring
Plasma-derived therapies (immunoglobulins, albumin, coagulation factors) plus recombinant and gene therapies for rare and serious diseases
Revenue
71.7%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
CSL Seqirus
Influenza vaccines (seasonal) plus pandemic/pre-pandemic preparedness and related government services
Revenue
13.9%
Structure
Oligopoly
Pricing
weak
Share
—
Peers
CSL Vifor
Iron deficiency therapies (IV iron) and nephrology/rare renal disease pharmaceuticals
Revenue
14.4%
Structure
Oligopoly
Pricing
weak
Share
—
Peers
Moat Claims
CSL Behring
Plasma-derived therapies (immunoglobulins, albumin, coagulation factors) plus recombinant and gene therapies for rare and serious diseases
Revenue_share and operating_profit_share are computed from FY2025 segment totals (Total segment revenue: CSL Behring US$11,158m of US$15,558m; Segment operating result: US$4,704m of US$6,827m). HY2026 Behring revenue was US$5.450b, down 7% in constant currency, and the May 2026 update cited US immunoglobulin inventory normalization and China albumin pricing pressure.
Supply Chain Control
Supply
Supply Chain Control
Strength
Durability
Confidence
Evidence
Vertically integrated model from donor to patient helps secure critical raw material (plasma), enables end-to-end quality control, and improves supply reliability versus less-integrated competitors.
Supply Chain Control moat: definition, examples, and stocks
Erosion risks
- Competitors expand plasma collection footprints and fractionation capacity
- Regulatory changes affecting plasma collection economics
- Sustained donor compensation inflation raising input costs
Leading indicators
- Plasma collections growth and cost per liter
- Fractionation utilization rates and lead times
- Gross margin trend for plasma-derived therapies
Counterarguments
- Other major plasma players are also vertically integrated
- Vertical integration is capital intensive and can reduce flexibility in downturns
Physical Network Density
Supply
Physical Network Density
Strength
Durability
Confidence
Evidence
Large plasma collection network and donor experience investments make replication slow and support scale advantages in plasma sourcing.
Physical Network Density moat: definition, examples, and stocks
Erosion risks
- New plasma centers from peers increase donor competition
- Local/community opposition or permitting friction for new centers
- Supply shocks (e.g., public health events) reducing donor availability
Leading indicators
- Net number of plasma centers and center productivity
- Donor return rates / repeat donor mix
- Peer announcements on new center openings
Counterarguments
- Well-capitalized peers can build networks over time
- Donors can switch centers if compensation/experience is better elsewhere
CSL Seqirus
Influenza vaccines (seasonal) plus pandemic/pre-pandemic preparedness and related government services
Revenue_share and operating_profit_share are computed from FY2025 segment totals (Total segment revenue: CSL Seqirus US$2,166m of US$15,558m; Segment operating result: US$1,027m of US$6,827m). HY2026 Seqirus revenue was US$1.646b, down 2% in constant currency; the May 2026 update said FY26 Seqirus performance is expected to be moderately stronger than prior guidance.
Government Contracting Relationships
Legal
Government Contracting Relationships
Strength
Durability
Confidence
Evidence
Pandemic and pre-pandemic agreements with governments provide durable institutional relationships and recurring preparedness revenue streams.
Government Contracting Relationships moat: definition, examples, and stocks
Erosion risks
- Government budget tightening and reprioritization of pandemic programs
- Policy-driven declines in vaccine uptake reduce seasonal volumes and weaken utilization
- Changes in procurement frameworks favoring lowest-cost suppliers
Leading indicators
- Number/value of government preparedness agreements
- Pandemic reservation fees trend
- Seasonal influenza vaccination rates in key markets
Counterarguments
- Government contracts can be retendered; incumbency is not permanent
- Political shifts can reduce funding regardless of supplier performance
CSL Vifor
Iron deficiency therapies (IV iron) and nephrology/rare renal disease pharmaceuticals
Revenue_share and operating_profit_share are computed from FY2025 segment totals (Total segment revenue: CSL Vifor US$2,234m of US$15,558m; Segment operating result: US$1,096m of US$6,827m). HY2026 Vifor revenue was US$1.236b, up 12% in constant currency, but CSL expects additional FY26/FY27 impairments mainly tied to Vifor intangible assets and under-utilised assets. On 26 June 2026 CHMP recommended revoking TAVNEOS marketing authorization in the EU over pivotal-trial data-handling concerns; no new EU/EEA patients are to start treatment while the European Commission decision is pending.
Insufficient segment-specific evidence to assign a moat claim.
Evidence
CSL Behring consists of three vertically integrated components that span the journey from donor to patient.
Direct statement supporting vertical integration as a structural advantage.
largest and most sophisticated plasma collection networks
Supports the physical network moat in plasma sourcing.
CSL has more than 30 agreements with governments around the world
Direct evidence of government relationship footprint relevant to pandemic preparedness.
Influenza pandemic facility reservation fees
Shows reported revenue line item tied to pandemic preparedness services.
Risks & Indicators
Erosion risks
- Competitors expand plasma collection footprints and fractionation capacity
- Regulatory changes affecting plasma collection economics
- Sustained donor compensation inflation raising input costs
- New plasma centers from peers increase donor competition
- Local/community opposition or permitting friction for new centers
- Supply shocks (e.g., public health events) reducing donor availability
Leading indicators
- Plasma collections growth and cost per liter
- Fractionation utilization rates and lead times
- Gross margin trend for plasma-derived therapies
- Net number of plasma centers and center productivity
- Donor return rates / repeat donor mix
- Peer announcements on new center openings
Research CSL elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.